Replies to post #242865 on Biotech Values

[dewophile]

I agree this could be a litmus test of sorts. The chair of the FTC is 20 years my junior. Hope she doesn’t overreach there are no obvious antitrust issues here

[DewDiligence]

MRK-SGEN $40B deal almost done—according to WSJ sources:

https://www.wsj.com/articles/merck-is-in-advanced-talks-to-buy-seagen-11657160827

The companies are discussing a price for Seagen above $200 a share and are seeking to seal a deal on or before the announcement of Merck’s quarterly earnings, set for July 28, the [sources] said.